Arpitha Parthasarathy

Ms. Arpitha Parthasarathy

Pitzer College, Claremont, California, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2022 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
GSGaithrri Shanmuganathan
Gaithrri Shanmuganathan
DODavit Orujyan
Davit Orujyan
WNWilliam Narinyan
William Narinyan
NPnicole poladian
nicole poladian
SDSanya Dhama
Sanya Dhama
Vishwanath VenketaramanVishwanath Venketaraman
Vishwanath Venketaraman
Considerable measures have been implemented in healthcare institutions to screen for and treat tuberculosis (TB) in developed countries; however, in low- and middle-income countries, many individuals still suffer from TB’s deleterious effects. TB is caused by an infection from the Mycobacterium tuberculosis (M. tb) bacteria. Symptoms of TB may range from an asymptomatic latent-phase affecting the pulmonary tract to a devastating active and disseminated stage that can cause central nervous system demise, musculoskeletal impairments, and genitourinary compromise. Following M. tb infection, cytokines such as interferons (IFNs) are released as part of the host immune response. Three main classes of IFNs prevalent during the immune defense include: type I IFN (α and β), type II IFN (IFN-γ), and type III IFN (IFN-λ). The current literature reports that type I IFN plays a role in diminishing the host defense against M. tb by attenuating T-cell activation. In opposition, T-cell activation drives type II IFN release, which is the primary cytokine mediating protection from M. tb by stimulating macrophages and their oxidative defense mechanisms. Type III IFN has a subsidiary part in improving the Th1 response for host cell protection against M. tb. Based on the current evidence available, our group aims to summarize the role that each IFN serves in TB within this literature review.

12 March 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
CACheldon Ann Alcantara
Cheldon Ann Alcantara
Ira GlassmanIra Glassman
Ira Glassman
KNKevin Nguyen
Kevin Nguyen
APArpitha Parthasarathy
Arpitha Parthasarathy
Vishwanath VenketaramanVishwanath Venketaraman
Vishwanath Venketaraman
Mycobacterium tuberculosis (M. tb) continues to be a leading cause of mortality within developing countries. The BCG vaccine to promote immunity against M. tb is widely used in developing countries and only in specific circumstances within the United States. However, current the literature reports equivocal data on the efficacy of the BCG vaccine. Critical within their role in the innate immune response, neutrophils serve as one of the first responders to infectious pathogens such as M. tb. Neutrophils promote effective clearance of M. tb through processes such as phagocytosis and the secretion of destructive granules. During the adaptative immune response, neutrophils modulate communication with lymphocytes to promote a strong pro-inflammatory response and to mediate the containment M. tb through the production of granulomas. In this review, we aim to highlight and summarize the role of neutrophils during an M. tb infection. Furthermore, the authors emphasize the need for more studies to be conducted on effective vaccination against M. tb.